BofA Securities Upgrades bluebird bio (BLUE) to Buy, 'positioned to lead in attractive sickle cell gene therapy market'
Tweet Send to a Friend
(Updated - July 19, 2023 6:11 AM EDT)
BofA Securities analyst Jason Gerberry upgraded bluebird bio (NASDAQ: BLUE) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
BofA Securities analyst Jason Gerberry upgraded bluebird bio (NASDAQ: BLUE) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
